Janssen
-
BeiGene in-licenses two clinical-stage oncology compounds
BeiGene will collaborate with Janssen in phase III clinical trials in melanoma and explore additional solid tumor indications in solid tumors prevalent in China and Asia.
Janssen | 15 October 2011
-
PRECOS signs service agreement with Janssen
Preclinical Oncology Services ( PRECOS ) has signed a service agreement with Janssen Pharmaceutica (Janssen). The global contract will see PRECOS provide clinical tumour material, tumour model development, target validation and drug efficacy work to …
Janssen | 21 January 2011
-
PPD and Janssen Pharmaceutica to Develop Therapeutic Compounds
PPD has entered an agreement with Janssen Pharmaceutica to develop and commercialize two Phase II-ready therapeutic compounds – one to treat diarrhea-predominant irritable bowel syndrome (IBS-d) and the other to treat complicated skin and skin stru…
Janssen | 11 January 2010
-
CHMP Delays Decision to Approve Zevtera
Janssen-Cilag has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has decided to delay the European Commission decision process on Zevtera (ceftobiprole medocaril) pending completion of a …
Janssen | 02 March 2009
-
Amgen licenses molecule to Ortho-McNeil-Janssen Pharmaceuticals
Amgen says it has licensed a clinical stage molecule for the treatment of chronic and neuropathic pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company. The terms of the agreement include a $50 million upfront pa…
Janssen | 08 August 2008
